<DOC>
	<DOC>NCT00072631</DOC>
	<brief_summary>The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.</brief_summary>
	<brief_title>Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Only patients with 0 to 1 performance status on the ECOG scale are eligible.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis of Stage IIIB or IV nonsmall cell lung cancer (histological or cytological). Received prior chemotherapy treatment for advanced, metastatic nonsmall cell lung cancer. Measurable disease per RECIST criteria. Adequate bone marrow, hepatic and renal function. Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years. Brain metastases that are unstable, require steroids, are lifethreatening or required radiation in the last 28 days. Known hypersensitivity to minocycline. History of serious cardiac disease that is not controlled. Serious eye conditions. Prior treatment with inhibitors of EGFR of any kind.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>erlotinib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>OSI-774</keyword>
</DOC>